乙醇胺作为抑郁症潜在生物标志物与治疗靶点
该研究在多个独立人脑脊液样本集及动物模型中验证乙醇胺(EA)与重性抑郁障碍(MDD)的关联。发现MDD患者脑脊液EA水平降低且与抑郁严重程度负相关,电休克治疗后升高,动物实验显示EA具有抗抑郁样行为效应。
要点
- MDD患者脑脊液EA水平显著降低,与抑郁严重程度负相关。
- 电休克治疗后脑脊液EA水平显著升高,且与HAMD子量表评分恢复相关。
- 大鼠腹腔注射LPS后脑脊液EA降低并出现抑郁焦虑快感缺失样行为,口服EA可产生抗抑郁样行为。
核心结论
- 脑脊液乙醇胺(EA)是MDD潜在的状态评估、治疗反应、亚型分型及动物模型验证的生物标志物,并可能成为精神疾病新分类框架和新治疗策略的研究工具。
研究设计与样本
- 研究使用人脑脊液样本集A(n=380)、B(n=13)、C(n=66)及动物模型(大鼠腹腔注射脂多糖0.5或1.0 mg/kg持续7天;口服EA 4周)进行验证与机制探索。
主要发现
- 样本集A中MDD患者脑脊液EA水平降低(P=0.00047,Cohen's d=-0.59),与抑郁严重程度负相关(Spearman's ρ=-0.29,P=0.00015),与脑脊液高香草酸(partial r=0.40,P=6.7E-8)和5-羟吲哚乙酸(partial r=0.26,P=0.00064)正相关。
- 样本集A中中重度抑郁患者无论是否用药均显示大效应(Cohen's d=-1.27至-1.14)。
- 样本集B中接受电休克治疗的患者脑脊液EA水平显著升高(P=0.0071;Cohen's d=0.90),且与汉密尔顿抑郁量表子量表评分恢复相关。
- 样本集C中MDD患者脑脊液EA水平降低(P=0.0037;Cohen's d=-0.91)。
- 大鼠腹腔注射0.5或1.0 mg/kg脂多糖7天后脑脊液EA水平显著降低(P=0.014;Cohen's d=-1.52和P=0.00020;d=2.31),并出现抑郁、焦虑及快感缺失样行为;口服EA 4周的大鼠表现出显著抗抑郁样行为(P=0.016;Cohen's d=-1.36)。
临床怎么用
- 脑脊液EA水平或可作为MDD辅助生物标志物,用于评估疾病状态、预测电休克治疗反应及辅助亚型分型。
- EA相关通路(如CHL1及轴突导向通路)可能为新型抗抑郁治疗策略提供研究靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated cerebrospinal fluid (CSF) ethanolamine (EA) levels in major depressive disorder (MDD), to validate our previous findings on EA (Ogawa et al., 2015) and broaden its biological context and translational relevance. Using human samples (sets A-C) and animal models, we explored the implications for replication, translational potential, therapeutic development, and mechanistic insight. In set A (n = 380), CSF EA levels were low in patients with MDD (P = 0.00047, Cohen's d = -0.59), negatively correlating with depression severity (Spearman's ρ = -0.29, P = 0.00015) and positively correlating with CSF homovanillic acid (partial r = 0.40, P = 6.7E - 8) and 5-hydroxyindoleacetic acid levels (partial r = 0.26, P = 0.00064). Patients with moderate-to-severe depression showed large effects regardless of medication (Cohen's d = -1.27 to -1.14). In set B (n = 13), CSF EA levels were significantly increased in patients who received electroconvulsive therapy (P = 0.0071; Cohen's d = 0.90), which was linked to Hamilton Depression Rating Scale subscale score recovery. In set C (n = 66), a novel multicenter-collected sample set, CSF EA levels were low in patients with MDD (P = 0.0037; Cohen's d = -0.91). Rats receiving 0.5 or 1.0 mg/kg lipopolysaccharide intraperitoneally for 7 days showed significantly reduced CSF EA levels (P = 0.014; Cohen's d = -1.52 and 0.00020; d = 2.31, respectively) and depressive-, anxiety-, and anhedonia-like behaviors. Rats orally administered EA for 4 weeks showed significant antidepressant-like behaviors (P = 0.016; Cohen's d = -1.36). Proteomic and bioinformatic analyses revealed 40 proteins that were significantly correlated with CSF EA levels. The top hit protein was CHL1 (partial r = 0.42, P = 1.5E - 9), and the axon guidance pathway was the most enriched (P = 3.4E - 20). EA is a potential CSF biomarker for mental state evaluation, treatment response, subtyping, and validation of MDD animal models and a promising research tool for developing a new classification framework for psychiatric disorders and novel therapeutic strategies.
引用
- Ogawa S, Hattori K, Hidese S, et al. Ethanolamine as a potential biomarker and therapeutic target for depressive disorder. Mol Psychiatry. 2026. PMID: 41986746. doi:10.1038/s41380-026-03559-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。